| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $176,907,760 ) (Continued on the next page) |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA243554 | A technological approach for performance status assessment in advanced cancer patients | 000 | 3 | NIH | 2/15/2022 | $509,284 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA258917 | Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer | 001 | 2 | NIH | 5/19/2022 | $36,803 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA243554 | A technological approach for performance status assessment in advanced cancer patients | 001 | 3 | NIH | 5/19/2022 | $45,275 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01HL130129 | Regulation of mesenchymal cells by epithelial Wnt ligands | 003 | 7 | NIH | 8/19/2022 | $608,155 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | U54CA274371 | Tumor Microenvironment Crosstalk Drives Early Lesions in Pancreatic Cancer | 000 | 1 | NIH | 9/21/2022 | $1,558,076 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | T32CA009666 | Research Training in Academic Medical Oncology | 002 | 28 | NIH | 5/20/2022 | $591,629 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01DE032018 | Harnessing the nervous system to overcome resistance to immunotherapy in oral cancer | 000 | 1 | NIH | 7/26/2022 | $673,034 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA269516 | Targeting head and neck cancer cells and the adverse tumor microenvironment with a novel small-molecule STAT3 inhibitor | 000 | 1 | NIH | 8/3/2022 | $671,730 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01EB032533 | Enhanced Biomechanical Modeling of the Breast for Womens Health | 000 | 1 | NIH | 6/6/2022 | $650,968 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 000 | 1 | NIH | 5/3/2022 | $556,148 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA269696 | Statistical Methods for Integration of Multiple Data Sources toward Precision Cancer Medicine | 000 | 1 | NIH | 6/1/2022 | $348,747 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA272945 | Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer | 000 | 1 | NIH | 8/15/2022 | $537,633 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | K99CA267678 | Positive Activities for Asian American Cancer Patients and Caregivers | 000 | 1 | NIH | 5/13/2022 | $98,733 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA261750 | Personalized Risk Prediction to Reduce Cardiovascular Disease in Childhood Cancer Survivors | 000 | 1 | NIH | 7/15/2022 | $510,311 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA260761 | Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome | 000 | 1 | NIH | 8/22/2022 | $646,311 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA236864 | DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS | 001 | 3 | NIH | 5/20/2022 | $29,647 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA236864 | DELINEATING THE EVOLUTION AND ECOLOGY OF CHEMORESISTANCE IN BREAST CANCER WITH SINGLE CELL GENOMICS | 000 | 3 | NIH | 11/19/2021 | $333,517 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA266099 | Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies | 000 | 1 | NIH | 7/5/2022 | $526,134 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01GM147064 | Overcoming the triple threat to diversity in the health science workforce: empowering the next gen. | 000 | 1 | NIH | 8/10/2022 | $373,476 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | K08CA263298 | Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis | 000 | 1 | NIH | 4/18/2022 | $260,405 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA266279 | BAF complex deregulation in lymphoma | 000 | 1 | NIH | 8/2/2022 | $701,610 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA274415 | In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy | 000 | 1 | NIH | 8/2/2022 | $612,076 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA258540 | Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma | 000 | 1 | NIH | 2/1/2022 | $596,833 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA266612 | Role of Heat Shock Protein 70 as a Mediator and Therapeutic Target in T-cell Lymphomas | 000 | 1 | NIH | 7/20/2022 | $499,410 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA218230 | Longitudinal therapeutic monitoring of colorectal cancer patients using exosome-based liquid biopsies | 000 | 5 | NIH | 6/27/2022 | $650,719 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA223772 | Cytoplasmic cyclin E is an early event for progression to invasive breast cancer | 001 | 5 | NIH | 5/19/2022 | $31,522 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA223772 | Cytoplasmic cyclin E is an early event for progression to invasive breast cancer | 000 | 5 | NIH | 1/13/2022 | $354,637 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA225701 | Strategies for Persistent Agitated Delirium in Palliative Care | 001 | 4 | NIH | 5/19/2022 | $35,465 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA225701 | Strategies for Persistent Agitated Delirium in Palliative Care | 000 | 4 | NIH | 1/31/2022 | $398,923 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA218139 | Medium-chain acyl-coenzyme A dehydrogenase as an essential feeder of glioblastoma multiforme | 001 | 5 | NIH | 5/19/2022 | $29,169 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA218139 | Medium-chain acyl-coenzyme A dehydrogenase as an essential feeder of glioblastoma multiforme | 000 | 5 | NIH | 1/12/2022 | $328,142 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01AI155582 | Neutrophil Extracellular Traps and Host Immunity | 000 | 2 | NIH | 2/7/2022 | $405,000 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01GM131639 | Regulation of RNA polymerase II pausing and directionality by ATP-dependent chromatin remodelers | 001 | 4 | NIH | 7/26/2022 | $45,729 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA239342 | Statistical methods and tools for cancer risk prediction in families with germline mutations in TP53 | 000 | 4 | NIH | 4/7/2022 | $351,518 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01GM131639 | Regulation of RNA polymerase II pausing and directionality by ATP-dependent chromatin remodelers | 000 | 4 | NIH | 3/10/2022 | $411,527 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA155243 | Pleiotropic functions of FOXC2 in EMT, stem cells and breast cancer progression | 001 | 10 | NIH | 7/11/2022 | $322,106 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01DK078900 | Role of Rho Kinase in Diabetic Nephropathy | 000 | 14 | NIH | 6/29/2022 | $356,400 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01DA032581 | Incentive salience and the neuropsychological underpinnings of cue-induced smoking relapse | 000 | 7 | NIH | 4/27/2022 | $359,579 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | F32CA239292 | Identifying the role of Ntrk1 in immunosuppression in Kras/p53 mutant lung cancer | 001 | 3 | NIH | 3/10/2022 | -$50,553 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | F32CA239292 | Identifying the role of Ntrk1 in immunosuppression in Kras/p53 mutant lung cancer | 000 | 3 | NIH | 12/1/2021 | $75,330 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01HL149751 | Epigenetic regulation of thrombopoiesis | 001 | 3 | NIH | 6/13/2022 | $32,400 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA236781 | Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi | 001 | 3 | NIH | 5/20/2022 | $33,867 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01GM130838 | Integrative approaches for decoding the function and regulation of unconventional RNA translation | 000 | 4 | NIH | 6/17/2022 | $356,446 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01HL149751 | Epigenetic regulation of thrombopoiesis | 000 | 3 | NIH | 12/17/2021 | $291,600 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA236781 | Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi | 000 | 3 | NIH | 11/23/2021 | $380,998 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA222253 | Validation of Critical 1q21 Vulnerabilities in Multiple Myeloma | 001 | 5 | NIH | 5/20/2022 | $29,361 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA222253 | Validation of Critical 1q21 Vulnerabilities in Multiple Myeloma | 000 | 5 | NIH | 1/4/2022 | $330,296 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01NS078152 | BK channel regulation by auxiliary LRR proteins | 000 | 10 | NIH | 5/11/2022 | $350,000 |
| | 2022 | 2022 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | K99CA256216 | Multilevel investigation of uncertain and reclassified genomic variants in clinical oncology | 001 | 2 | NIH | 9/15/2022 | $0 |
|
